Cystic Fibrosis

Participation in the Cystic Fibrosis Patient Registry (IRB Registration # 00003104)
Investigator: Zanni, Robert MD
Study Status: Open
Sponsor: Cystic Fibrosis Foundation
Contact: Bridget Marra 732.222.4474

The EPIC Observational Study:
Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF (IRB Registration # 00003104)
Investigator: Zanni, Robert MD
Study Status: Open
Sponsor: Cystic Fibrosis Foundation
Contact: Bridget Marra 732.222.4474

CFFC-OB-11:
A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors.
Investigator: Zanni, Robert MD
Study Status: Open
Sponsor: Cystic Fibrosis Foundation
Contact: Bridget Marra 732.222.4474

OPTIMIZE-IP-12:
OPTIMIZing Treatment for Early Pseudomonas aeruginosa Infection in Cystic Fibrosis The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. (IRB Registration #00003104)
Investigator: Zanni, Robert MD
Study Status: Open
Sponsor: Seattle Children's Research Institute
Contact: Bridget Marra 732.222.4474

PTC124-GD-021-CF:
A Phase 3 Efficacy And Safety Study Of Ataluren (PTC124®) In Patients With Nonsense Mutation Cystic Fibrosis. (IRB Registration #00003104)
Investigator: Zanni, Robert MD
Study Status: Open
Sponsor: PTC Therapeutics, Inc.
Contact: Bridget Marra 732.222.4474

VX14-661-106:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CF
Investigator: Zanni, Robert MD
Study Status: Open
Sponsor: Vertex Pharmaceuticals, Inc.
Contact: Bridget Marra 732.222.4474